Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 8—August 2024
Research
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance
Figure 1
![Treatment pathways for new TB patients in study of potential of pan-TB treatment to drive emergence of novel resistance, comparing a pan-TB treatment scenario (A) with the standard-of-care scenario (B). Retreatment pathways are shown in Appendix Figure 1. BR-TB, diarylquinoline-resistant TB; RR-TB, rifampin-resistant TB; RS-TB, rifampin-susceptible TB; TB, tuberculosis; XR-TB, TB resistant to additional novel drug X; R DST, rifampin drug-susceptibility testing; B DST, diarylquinoline susceptibility testing; X DST, other novel drug (or drugs) susceptibility testing.](/eid/images/24-0541-F1.jpg)
Figure 1. Treatment pathways for new TB patients in study of potential of pan-TB treatment to drive emergence of novel resistance, comparing a pan-TB treatment scenario (A) with the standard-of-care scenario (B). Retreatment pathways are shown in Appendix Figure 1. BR-TB, diarylquinoline-resistant TB; RR-TB, rifampin-resistant TB; RS-TB, rifampin-susceptible TB; TB, tuberculosis; XR-TB, TB resistant to additional novel drug X; R DST, rifampin drug-susceptibility testing; B DST, diarylquinoline susceptibility testing; X DST, other novel drug (or drugs) susceptibility testing.